Last updated: 2026-09-16 09:46:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
KALA BIO, Inc. (KALA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.51, with a market capitalisation of $10.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.49 to $1,030.00. This page covers its latest market performance, valuation, price trends and company information.
$10.46M | |
$0.51 | |
$66,808.19 | |
$0.49 | |
$0.51 | |
2.00 | |
342.22K | |
-- | |
$1,030.00 | |
$0.49 | |
-- | |
-- |
KALA BIO, Inc. (KALA) is trading at $0.51 in pre-market trading as of 2026-09-16 08:41:00, up 1.04% ($0.01) from the previous close of $0.51
Pre-market trading shows how investors are pricing KALA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, KALA BIO, Inc. (KALA) moved from $0.51 to $0.51, representing a gain of 1.12% ($0.01).
The stock traded between $0.49 and $0.61 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 250.86 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.0%
KALA is currently trading at $0.51, placing it 0.0% of the way from its 52-week low of $0.49 to its 52-week high of $1,030.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of KALA BIO, Inc. (KALA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.